WASHINGTON (AP) — For Republicans, it's an irresistible trifecta: A bill that gives them an election-season chance to say they're fighting to protect jobs and cut taxes, even as it erodes financing for President Barack Obama's health care overhaul they despise.
So though it is destined to die in the Democratic-run Senate, GOP leaders plan to push legislation through the House this week to repeal an excise tax on the makers of medical devices sold in the U.S. The tax, which takes effect next January, applies to everything from replacement joints to imaging equipment but exempts consumer products like eyeglasses and bandages.
Democrats say the growing medical device industry can afford the 2.3 percent tax. They describe the tax as part of the price device manufacturers and other providers agreed to pay in exchange for the tens of millions of new customers they will get through the sweeping 2010 health care law's expansion of health insurance coverage.
That's not the view of Republicans or the medical device industry, which has lobbied Congress heavily to kill the tax before it takes hold. GOP lawmakers have named their legislation the Protect Medical Innovation Act, and insist it is not aimed at dismantling Obama's health care law.
"That's not part of my agenda," said chief sponsor Rep. Erik Paulsen, R-Minn., whose state is one of the centers of the nation's $130 billion-a-year medical device industry. He said the tax would eat up dollars that otherwise might go toward research and development — and jobs.
Repealing the tax would cost the government an estimated $29 billion over the coming decade — a small fraction of the health care law's cost.
Republicans would pay for repeal by making it easier for the government to recover overpayments of federal insurance subsidies that lower-earning people may receive under the health care overhaul. In hopes of broadening the bill's appeal, provisions are also being added that would let people recover up to $500 if they don't use all the money in their health flexible spending accounts, and easing restrictions against using some tax-favored health accounts to buy over-the-counter drugs.
The House vote will occur as the Supreme Court prepares to rule later this month on the constitutionality of the health care law.
Democrats also hope to play some offense in the House debate.
Rep. Sander Levin, D-Mich., said he will argue that Republicans are trying to unravel the health care overhaul instead of working on legislation to strengthen the economy, such as tax incentives proposed by Obama.
Republicans think taking no action on the economy "helps defeat the president" in November's election, Levin said. "They think it's good politics, but it's irresponsible."
For good measure, Democrats say the measure has no chance in the Senate.
"Of course we're not going to bring it up," said Adam Jentleson, spokesman for Senate Majority Leader Harry Reid, D-Nev., citing Democrats' desire to defend the health care law.
But the dividing line is not completely partisan. Eleven of Paulsen's 238 co-sponsors are Democrats frommedical technology centers like Massachusetts, Pennsylvania and Utah. Minnesota's two Democratic senators, Al Franken and Amy Klobuchar, say they favor eliminating the tax as has Democrat Elizabeth Warren, who is challenging GOP Sen. Scott Brown in Massachusetts.
Brown and Sen. Orrin Hatch, R-Utah, have introduced similar bills.
U.S. medical device makers employ more than 400,000 people. The industry's largest trade group, AdvaMed, cites a study it commissioned that concluded the new tax could cost 43,000 of those jobs — about 10 percent — while doubling companies' tax bills and encouraging them to move plants overseas. The findings are often quoted by Republicans.
Critics say the study is biased and ignores the extra customers the industry will get as the health care law phases in. They also say the law won't force companies to move jobs overseas since it applies to all U.S. sales, no matter where the product is made.
"It doesn't make any sense," Robert Town, professor of health care management at the University of Pennsylvania's Wharton School, said of such claims. He and other analysts said they believe the overall industry impact of the tax would be modest.
Though the industry is dominated by huge companies like Medtronic of Minneapolis and Boston Scientific of Natick, Mass., AdvaMed says most of its 300 members have 30 or fewer workers. The Medical DeviceManufacturers Association, representing many small and medium-size companies, cites similar figures.
Industry officials say young companies could be especially hurt because the tax is levied on total sales, not profits. If a business sells $100 million worth of products and a $4 million profit, the $2.3 million it would owe would erode more than half its earnings — excluding federal and state corporate taxes.
"It's going to cost jobs in our industry," said AdvaMed lobbyist J.C. Scott. For companies breaking even, he said, the tax "can push them to a place where they just can't move their business forward."
Company executives said their industry was too competitive to pass their added costs to customers. Town and other analysts said they believed that eventually, as with most excise taxes, those costs would be built into manufacturers' prices.
Kem Hawkins, president of stent maker Cook Medical of Bloomington, Ind., said a 2.3 percent tax would cost his company around $20 million, erasing 15 percent of earnings.
Combined with federal and state taxes, he said he'd be paying a tax rate of 58 percent. Opening a new plant employing 300 workers can cost $13 million, he said.
"It's the tipping point," he said of the excise tax. While he said he would protect the company's 7,500 U.S. jobs, he added, "Our new manufacturing is going abroad, make no mistake about it."
Gregory Sorensen, CEO of Siemens Healthcare North America, a giant maker of scanning devices, said the taxwould force him to consider savings from reduced investments or U.S. jobs. He said his company has about $2 billion in annual sales and $500 million in profits in the U.S. — meaning the tax could cost Siemens about $46 million a year.
"The money has to come from somewhere," he said.
___
Associated Press writer Ricardo Alonso-Zaldivar contributed to this report.
Minn. Democrats in bind over medical device tax
ST. PAUL, Minn. (AP) — Democrats in Minnesota's congressional delegation are in a bind over a bill by Republican U.S. Rep. Erik Paulsen to eliminate a tax on medical devices like those made by Medtronic and other Minnesota companies.
The 2.3 percent tax on devices such as pacemakers and stents provides a vital $29 billion over the next decade for the federal health-care plan backed by President Barack Obama. Democrats justify the tax on the grounds that the health care law expands insurance coverage to 30 million people who were previously uninsured, and with all those new patients, the industry is likely to see demand for its products expand.
But Paulsen said the tax endangers 35,000 jobs in Minnesota and thousands more elsewhere. His bill to repeal it has 240 co-sponsors, including 11 Democrats, and it's expected to get a vote later this week.
"A lot of Democrats, they're fearful to acknowledge that the new health care law has a lot of imperfections, and privately they'll tell you there's a lot of problems with it," Paulsen told Minnesota Public Radio (http://bit.ly/LrmQHW).
Democratic U.S. Sens. Amy Klobuchar and Al Franken support repealing the tax.
"I realize that cutting the tax would mean less money for the health care bill," Klobuchar said at a medical industry event last week. She said the medical device tax was added to the health care plan at the last minute.
But that's not quite what happened back when Congress hammered out the plan, said Paul Van de Water, a fellow at the liberal-leaning Center for Budget and Policy Priorities.
"The industry was negotiating for a form of the tax which they thought was better, and they in fact got one," Van de Water said. He said the industry now wants a better deal: no tax at all.
Democratic Rep. Tim Walz said he's sensitive to the industry's opposition, but he considers the tax a key funding mechanism for the health care plan.
"My concern on this is, OK, so you repeal this, but no one has health care — who's going to buy the devices?" Walz said. "How are you going to make any money if no one has health care or can afford them? It doesn't make any sense."
Democratic Rep. Betty McCollum opposed the tax before the bill passed, but now wants to know how Republicans will pay for the $29 billion cost of repealing it. She said she would support repealing the tax if Republicans offer an offsetting budget cut she could support.
Late last week, House Republican leaders proposed to pay for the tax cut by trimming some subsidies designed to make health insurance affordable for middle- and low-income residents.
Staffers for the House Ways and Means Committee, which first examined the plan in April as a potential budget-saving measure, testified that it could result in 350,000 fewer people gaining insurance under the federal health law. But Republicans argue that the measure does nothing more than make sure people don't get benefits to which they're not entitled.
It remains to be seen how the new GOP plan will be received in the Democratic-controlled House. Spokepeople for Klobuchar and Franken said they hadn't seen draft language but were reviewing the plan over the weekend.
Klobuchar spokesman Linden Zakula told the Star Tribune (http://bit.ly/LZXsrL ) that the senator "will look at any and all proposals to get this done."